Ipamorelin + CJC-1295 Peptide Stack

This peptide stack integrates the unique properties of Ipamorelin and CJC-1295 to target the growth hormone axis effectively. CJC-1295 serves as a long-acting GHRH analogue, providing a sustained stimulation of GH release, while Ipamorelin induces a more immediate, pulsatile release through its action on the ghrelin receptor. The complementary mechanisms of these peptides not only amplify GH output but also allow researchers to investigate the nuances of GH signaling pathways in preclinical models. Studies suggest that this stack can facilitate deeper understanding of GH's role in various physiological processes, including muscle hypertrophy, fat metabolism, and recovery from injury.

Ipamorelin is recognized as one of the most selective growth hormone secretagogues available for research purposes. As a synthetic pentapeptide with a molecular weight of approximately 711.86 g/mol (C38H49N9O5), it is designed to stimulate GH release from the pituitary gland while minimizing effects on cortisol, prolactin, and appetite. Research indicates that Ipamorelin binds selectively to the Growth Hormone Secretagogue Receptor (GHS-R1a) on somatotroph cells, enhancing intracellular cAMP levels and activating protein kinase A, which promotes GH secretion. Its unique binding profile prevents the unwanted hormonal spikes associated with other secretagogues like GHRP-6. The half-life of Ipamorelin is approximately 2 hours, necessitating multiple daily doses in research protocols. Notably, evidence suggests that it does not lead to receptor desensitization, allowing for extended use without a decline in effectiveness, which is crucial for long-term studies.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), initially developed for the treatment of HIV-associated lipodystrophy. This peptide exists in two forms: CJC-1295 with Drug Affinity Complex (DAC) and Mod GRF 1-29 without DAC. The DAC version offers an extended half-life of 5.8 to 8.1 days, allowing for prolonged GH stimulation, while the Mod GRF 1-29 variant has a shorter half-life of about 30 minutes, which mimics natural pulsatile GH release. Clinical trials have shown that CJC-1295 can induce significant increases in GH and IGF-1 levels, with dose-dependent effects observed in healthy adults. However, the continuous GH elevation from the DAC version may lead to potential receptor desensitization and insulin resistance, raising concerns about its long-term use. In contrast, the pulsatile release pattern associated with Mod GRF 1-29 preserves physiological feedback mechanisms, potentially reducing adverse effects while facilitating research into GH's metabolic roles.